Lemborexant vs Zopiclone vs Clonidine for Insomnia Treatment in Chronic Pain Patients
Launched by SALEM ANAESTHESIA PAIN CLINIC · Nov 8, 2022
Trial Information
Current as of May 07, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating how well three different treatments—Lemborexant, Zopiclone, and Clonidine—help patients with chronic pain who also struggle with insomnia (difficulty sleeping). The study involves 150 adult participants who will try each of these medications on alternate nights for three weeks. Throughout the trial, participants will keep a special sleep diary to track their sleep quality, pain levels, and any side effects they may experience. This will help researchers understand which medication works best for improving sleep and managing pain.
To join the study, participants must be adults experiencing chronic pain and severe insomnia, have tried other non-medication treatments without success, and have been taking Zopiclone regularly for at least three months. They also need to be able to accurately record their sleep and pain scores. However, individuals with certain conditions, like sleep apnea or severe obesity, or those taking specific medications, will not be eligible to participate. Throughout the trial, participants can expect close monitoring of their sleep and pain responses to the medications, helping to contribute valuable information to improve treatment options for people with similar struggles.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • adult chronic pain patients
- • good treatment compliance
- • severe chronic insomnia
- • failure of non-pharmacologic sleep therapy
- • regular zopiclone therapy for 3 months or more
- • regular sleep diary
- • regular pain diary
- • informed consent for diary review
- • consent for clinical record quality assurance review
- Exclusion Criteria:
- • obstructive sleep apnoea
- • body mass index (BMI) ≥40
- • organ insufficiency
- • cognitive disorder
- • inability to provide consent
- • major neuropsychiatric disorder
- • unreliable diary
- • cannabis use
- • regular alcohol intake
- • stimulant use
- • substance abuse
- • poor treatment compliance
- • high dose opioid
- • gabapentinoid use
- • sedative use
- • mild insomina
- • irregular zopiclone intake
- • regular zopiclone therapy for less than 3 months
- • previous adverse/allergic reactions to clonidine or zopiclone
About Salem Anaesthesia Pain Clinic
Salem Anaesthesia Pain Clinic is a leading clinical trial sponsor dedicated to advancing research in pain management and anaesthesia. With a focus on innovative therapies and cutting-edge techniques, the clinic collaborates with healthcare professionals and researchers to conduct rigorous clinical trials aimed at improving patient outcomes. Our commitment to ethical standards and patient safety ensures that all trials are conducted with the highest level of integrity and transparency. By leveraging our expertise and state-of-the-art facilities, Salem Anaesthesia Pain Clinic strives to contribute valuable insights to the field of pain management, ultimately enhancing the quality of life for individuals suffering from chronic pain.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Surrey, British Columbia, Canada
Patients applied
Trial Officials
Olu Bamgbade, MD,FRCPC
Principal Investigator
Salem Anaesthesia Pain Clinic
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials